Patient Name : Ms.

RINKI DEY Collected : 03/Jun/2023 10:20AM

Age/Gender : 30 Y 9 M 8 D /F Received : 03/Jun/2023 01:37PM
UHID/MR No : AGHL.0001576571 Reported : 03/Jun/2023 02:01PM
Visit ID : DSDYOPV952 Status : Final Report
Ref Doctor : DR J BHATTACHARYA Client Name : PUP 24X7_CREDIT
IP/OP NO : Patient location : UTTAR PALLY,Kolkata

DEPARTMENT OF BIOCHEMISTRY
GLUCOSE FASTING & PP

Test Name Result Status Unit Bio. Ref. Range Method

GLUCOSE, FASTING , NAF PLASMA 83 Normal mg/dL 70-100 GOD - POD

Comment:
As per American Diabetes Guidelines
Fasting Glucose Values in mg/d L Interpretation
<100 mg/dL Normal
100-125 mg/dL Prediabetes
≥126 mg/dL Diabetes

Page 1 of 5

SIN No:BI14480389
Patient Name : Ms.RINKI DEY Collected : 03/Jun/2023 10:20AM
Age/Gender : 30 Y 9 M 8 D /F Received : 03/Jun/2023 04:25PM
UHID/MR No : AGHL.0001576571 Reported : 03/Jun/2023 05:25PM
Visit ID : DSDYOPV952 Status : Final Report
Ref Doctor : DR J BHATTACHARYA Client Name : PUP 24X7_CREDIT
IP/OP NO : Patient location : UTTAR PALLY,Kolkata

DEPARTMENT OF BIOCHEMISTRY
GLUCOSE FASTING & PP

Test Name Result Status Unit Bio. Ref. Range Method

GLUCOSE, POST PRANDIAL (PP), 86 Normal mg/dL 70-140 GOD - POD
2 HOURS , NAF PLASMA

Comment:
It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each
other.
Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive
hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin
preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Ref: Marks medical biochemistry and clinical approach

Page 2 of 5

SIN No:BI14480390
Patient Name : Ms.RINKI DEY Collected : 03/Jun/2023 10:20AM
Age/Gender : 30 Y 9 M 8 D /F Received : 03/Jun/2023 01:33PM
UHID/MR No : AGHL.0001576571 Reported : 03/Jun/2023 03:15PM
Visit ID : DSDYOPV952 Status : Final Report
Ref Doctor : DR J BHATTACHARYA Client Name : PUP 24X7_CREDIT
IP/OP NO : Patient location : UTTAR PALLY,Kolkata

DEPARTMENT OF BIOCHEMISTRY

Test Name Result Status Unit Bio. Ref. Range Method

HBA1C (GLYCATED HEMOGLOBIN) , WHOLE BLOOD-EDTA
HBA1C, GLYCATED HEMOGLOBIN 4.1 Normal % HPLC
ESTIMATED AVERAGE GLUCOSE 71 mg/dL Calculated
(eAG)
Note: HbA1c estimation by HPLC has showed a variant window. Presence of variant window may alter the HbA1c result. Kindly
correlate clinically. If clinical suspicion high, advised for Hb-typing. Serum fructosamine study for monitoring short-term diabetic
control.

Comment:
Reference Range as per American Diabetes Association (ADA):
REFERENCE GROUP HBA1C IN %
NON DIABETIC ADULTS >18 YEARS <5.7
AT RISK (PREDIABETES) 5.7 – 6.4
DIAGNOSING DIABETES ≥ 6.5
DIABETICS
· EXCELLENT CONTROL 6–7
· FAIR TO GOOD CONTROL 7–8
· UNSATISFACTORY CONTROL 8 – 10
· POOR CONTROL >10
Note: Dietary preparation or fasting is not required.

1. A1C test should be performed at least two times a year in patients who are meeting treatment goals (and who have stable
glycemic control).
2. Lowering A1C to below or around 7% has been shown to reduce microvascular and neuropathic complications of type 1
and type 2 diabetes. When mean annual HbA1c is <1.1 times ULN (upper limit of normal), renal and retinal complications
are rare, but complications occur in >70% of cases when HbA1c is >1.7 times ULN.
3. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or
decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect
erythrocyte survival are present. Fructosamine may be used as an alternate measurement of glycemic control

Page 3 of 5

SIN No:BI14480387
Patient Name : Ms.RINKI DEY Collected : 03/Jun/2023 10:20AM
Age/Gender : 30 Y 9 M 8 D /F Received : 03/Jun/2023 01:33PM
UHID/MR No : AGHL.0001576571 Reported : 03/Jun/2023 03:15PM
Visit ID : DSDYOPV952 Status : Final Report
Ref Doctor : DR J BHATTACHARYA Client Name : PUP 24X7_CREDIT
IP/OP NO : Patient location : UTTAR PALLY,Kolkata

DEPARTMENT OF BIOCHEMISTRY

Page 4 of 5

SIN No:BI14480387
Patient Name : Ms.RINKI DEY Collected : 03/Jun/2023 10:20AM
Age/Gender : 30 Y 9 M 8 D /F Received : 03/Jun/2023 01:52PM
UHID/MR No : AGHL.0001576571 Reported : 03/Jun/2023 02:24PM
Visit ID : DSDYOPV952 Status : Final Report
Ref Doctor : DR J BHATTACHARYA Client Name : PUP 24X7_CREDIT
IP/OP NO : Patient location : UTTAR PALLY,Kolkata

DEPARTMENT OF BIOCHEMISTRY

Test Name Result Status Unit Bio. Ref. Range Method

LIPID PROFILE , SERUM
TOTAL CHOLESTEROL 147 Normal mg/dL <200 CHE/CHO/POD
TRIGLYCERIDES 72 Normal mg/dL <150 Enzymatic
HDL CHOLESTEROL 50 Normal mg/dL >40 CHE/CHO/POD
NON-HDL CHOLESTEROL 97 Normal mg/dL <130 Calculated
LDL CHOLESTEROL 82.6 Normal mg/dL <100 Calculated
VLDL CHOLESTEROL 14.4 Normal mg/dL <30 Calculated
CHOL / HDL RATIO 2.94 Normal 0-4.97 Calculated

Comment:
Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

Desirable Borderline High High Very High

TOTAL CHOLESTEROL < 200 200 - 239 ≥ 240
TRIGLYCERIDES <150 150 - 199 200 - 499 ≥ 500
Optimal < 100
LDL 130 - 159 160 - 189 ≥ 190
Near Optimal 100-129
HDL ≥ 60
Optimal <130;
NON-HDL CHOLESTEROL 160-189 190-219 >220
Above Optimal 130-159

Measurements in the same patient can show physiological and analytical variations.
NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.

*** End Of Report ***

Page 5 of 5

SIN No:BI14480388